Delshad Ahmad, MD

There are 20 Clinical Trials currently being conducted by Delshad Ahmad, MD
Title
Type
Enrollment
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer
Closed
A022102: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Cancer
Open
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Cancer
Open
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Cancer
Open
CompassHER2-T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer
Closed
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer
Closed
A032101: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Cancer
Closed
Study of Personalized Cancer Therapy to Determine Response and Toxicity. UCSD-HRPP-130794
Cancer
Open
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer
Closed
S1900J:Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Cancer
Open
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Cancer
Open
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Cancer
Closed
Breast Cancer WEight Loss Study (BWEL Study)
Cancer
Closed
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer
Open
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
Cancer
Open
A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer
Open
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Cancer
Open
NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Cancer
Open
S2209-A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Cancer
Open
Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
Cancer
Open
Delshad Ahmad, MD
LIVE